Provided by Tiger Trade Technology Pte. Ltd.

HARBOR HEALTH CARE ETF

32.96
-0.3796-1.14%
Post-market: 33.050.0854+0.26%16:10 EDT
Volume:1K
Turnover:46.07K
Market Cap:42.03M
PE:- -
High:33.17
Open:33.17
Low:32.95
Close:33.34
52wk High:35.61
52wk Low:27.50
Shares:1.28M
Float Shares:1.28M
Volume Ratio:0.18
T/O Rate:0.11%
Dividend:0.08
Dividend Rate:0.23%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Health Advisory: Avoid Misusing Weight-Loss Medications, Prioritize Evaluation Before Treatment

Deep News
·
56 mins ago

Retension Pharmaceuticals, TRex Bio File for US IPO as Biotech Momentum Continues

Reuters
·
11 hours ago

Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide

TIPRANKS
·
13 hours ago

Sector Update: Healthcare

MT Newswires Live
·
14 hours ago

US FDA Approves Lilly Inluriyo-Verzenio Combo for ESR1-Mutated Metastatic Breast Cancer

Reuters
·
15 hours ago

U.S. FDA Approves Inluriyo (Imlunestrant) in Combination with Verzenio (Abemaciclib) for Adults with Er+, Her2-, Esr1-Mutated Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
15 hours ago

Eli Lilly - Inluriyo with Verzenio NOW Available in the United States

THOMSON REUTERS
·
15 hours ago

Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

TIPRANKS
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), BioMarin Pharmaceutical (BMRN) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Yesterday

All 50 States Sign up for Trump's Medicaid Most-Favored-Nation Plan

Reuters
·
Yesterday

When Weight Loss Isn't the Goal of Taking a GLP-1

Dow Jones
·
Yesterday

InfuSystem to Host Investor Webcast on Strategy

TIPRANKS
·
Yesterday

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

Moderna Inc. Stock Climbs 8.5%, Outperforms Peers

Dow Jones
·
Yesterday

Eli Lilly & Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

Ultragenyx confirms FDA approval of Fayuvi

TIPRANKS
·
Yesterday

Wolfe Research Initiates Rhythm Pharmaceuticals at Outperform

MT Newswires Live
·
Sep 17

Goldman Sachs Adjusts Eli Lilly Price Target to $1,371 From $1,367, Maintains Buy Rating

MT Newswires Live
·
Sep 17

Nuvation Bio announces FDA approval of sNDA for Ibtrozi

TIPRANKS
·
Sep 17

Rhythm Pharmaceuticals initiated with an Outperform at Wolfe Research

TIPRANKS
·
Sep 17